HemOnc Today New York

The latest news from the annual meeting, including video perspective from faculty members and attendees.


Meeting NewsVideo

VIDEO: Meeting offers insights into application of CAR T-cell therapy for hematologic malignancies

March 12, 2018
NEW YORK — In this video commentary from HemOnc Today New York, program co-chair David L. Porter, MD, discusses some of the take-home messages…
Meeting News

CAR T-cell therapy holds promise for multiple myeloma

March 12, 2018
NEW YORK — Cellular immunotherapies such as chimeric antigen receptor therapy are a promising approach for treatment of multiple myeloma…
Meeting News

Targeted therapies effective for acute lymphoblastic leukemia

March 10, 2018
NEW YORK — Targeted therapies such as inotuzumab and blinatumomab appear associated with high rates of complete molecular remission in patients…
Video

VIDEO: New data emerges for adjuvant treatment of melanoma

March 10, 2018
NEW YORK — In this video commentary from HemOnc Today New York, co-program chair Sanjiv S. Agarwala, MD, summarizes highlights from the…
Meeting NewsVideo

VIDEO: CAR T-cell therapy has ‘incredible potency’ in chronic lymphocytic leukemia

March 10, 2018
NEW YORK — In this video commentary from HemOnc Today New York, co-program chair David L. Porter, MD, discussed the use of chimeric antigen…
Meeting News

CAR T-cell therapy ‘holds great promise’ for advanced chronic lymphocytic leukemia

March 10, 2018
NEW YORK — Chimeric antigen receptor T-cell therapy “holds great promise” for patients with advanced relapsed or refractory chronic…
Meeting NewsVideo

VIDEO: Onset, frequency of toxicities vary between CTLA-4, PD-L1 agents

March 9, 2018
NEW YORK — In this video commentary from HemOnc Today New York, Young Kwang Chae, MD, MPH, MBA, discussed
Meeting NewsVideo

VIDEO: New data emerges for immunotherapy in frontline treatment of advanced lung cancer

March 9, 2018
NEW YORK — In this video commentary from HemOnc Today New York, Taofeek K. Owonikoko, MD, PhD, discussed the existing and emerging evidence of…
Meeting News

Treatment of recurrent or metastatic head and neck cancer remains challenging

March 9, 2018
NEW YORK — Treatment of recurrent or metastatic head and neck cancer is challenging given the availability of only a few treatment options…
Meeting News

Salvage immunotherapy viable for non-small cell lung cancer

March 9, 2018
NEW YORK — Immunotherapy remains a viable option for pretreated patients with non-small cell lung cancer, but the data are rapidly evolving…